- BridgeBio to host investor call today at 1:30 pm ET to discuss its two most advanced RAS precision oncology programs – KRASG12C GTP/GDP dual inhibitor development candidate BBO-8520, and its. | October 17, 2022
New Hampshire's Strangest Attractions and Landmarks - New Hampshire Magazine nhmagazine.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nhmagazine.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company that focuses on genetic diseases and cancers, is announcing.